Polypill for prevention of cardiovascular disease in an Urban Iranian population with special focus on nonalcoholic steatohepatitis: A pragmatic randomized controlled trial within a cohort (PolyIran - Liver) – Study protocol

Archives of Iranian Medicine

Volumn 18, Issue 8, 2015, Pages 515-523

  Merat, Shahin ^a,b   Poustchi, Hossein ^a,b   Hemming, Karla ^c   Jafari, Elham ^a,d   Radmard, Amir Reza ^e   Nateghi, Alireza ^f   Khuzani, Abolfazl Shiravi ^e   Khoshnia, Masoud ^g   Marshall, Tom ^c   Malekzadeh, Reza ^a,b,d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f Alborz Darou Pharmaceutical Co   (Iran)

^g GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Atherosclerosis; Iran; Liver; Primary prevention; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ATORVASTATIN; HYDROCHLOROTHIAZIDE; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; DIURETIC AGENT; DRUG COMBINATION; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLINDNESS; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; FOLLOW UP; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; MORTALITY; NONALCOHOLIC FATTY LIVER; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; CARDIOVASCULAR DISEASES; DRUG COMBINATION; IRAN; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; URBAN POPULATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ASPIRIN; ATORVASTATIN CALCIUM; CARDIOVASCULAR DISEASES; DIURETICS; DRUG COMBINATIONS; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IRAN; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PLATELET AGGREGATION INHIBITORS; URBAN POPULATION; VALSARTAN;

EID: 84939526102     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Merat S, Malekzadeh R. Prevention of non-communicable diseases: what can be done? Arch Iran Med. 2013; 16(3): 136-7.
2. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003; 326(7404): 1419.
3. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013; 1: CD004816.
4. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373(9678): 1849-60.
5. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366(9493): 1267-78.
6. ulbulia R, Bowman L, Wallendszus K, Parish S, Armitage J, Peto R, et al. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet 2011; 378(9808): 2013-20.
7. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009; 338: b1665.
8. Karbasi-Afshar R, Saburi A, Khedmat H. Cardiovascular disorders in the context of non-alcoholic Fatty liver disease: a literature review. J Tehran Heart Cent. 2014; 9(1): 1-8.
9. Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hematology. 2010; 51(2): 595-602.
10. Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol. 2012; 10(6): 646-50.
11. Min HK, Kapoor A, Fuchs M, Mirshahi F, Zhou H, Maher J, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab. 2012; 15(5): 665-74.
12. Lai SW, Liao KF, Lai HC, Muo CH, Sung FC, Chen PC. Statin use and risk of hepatocellular carcinoma. Eur J Epidemiol. 2013; 28(6): 485-92.
13. Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramin H. Statins for non-alcoholic fatty liver disease and non-alcoholic steato- hepatitis. Cochrane Database Syst Rev. 2013; 12: CD008623.
14. Paschos P, Tziomalos K. Nonalcoholic fatty liver disease and the re- nin-angiotensin system: Implications for treatment. World J Hepatol. 2012; 4(12): 327-31.
15. Sahasrabuddhe VV, Gunja MZ, Graubard BI, Trabert B, Schwartz LM, Park Y, et al. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst. 2012; 104(23): 1808-14.
16. Malekzadeh F, Marshall T, Pourshams A, Gharravi M, Aslani A, Nat- eghi A, et al. A pilot double-blind randomised placebo-controlled trial of the effects of fìxed-dose combination therapy ('polypill') on cardiovascular risk factors. Int J Clin Pract. 2010; 64(9): 1220-7.
17. Ostovaneh MR, Poustchi H, Hemming K, Marjani H, Pourshams A, Nateghi A, et al. Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial. Eur J Prev Cardiol. 2014.
18. Pourshams A, Khademi H, Malekshah AF, Islami F, Nouraei M, Sad- jadi AR, et al. Cohort Profile: The Golestan Cohort Study--a prospective study of oesophageal cancer in northern Iran. Int J Epidemiol. 2010; 39(1): 52-9.
19. Zelen M. A new design for randomized clinical trials. N Engl J Med. 1979; 300(22): 1242-5.
20. Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007; 102(12): 2708-15.
21. Ayonrinde OT, Olynyk JK, Beilin LJ, Mori TA, Pennell CE, de Klerk N, et al. Gender-specific differences in adipose distribution and adipo- cytokines influence adolescent nonalcoholic fatty liver disease. Hepatology. 2011; 53(3): 800-9.
22. Kim SK, Kim HJ, Hur KY, Choi SH, Ahn CW, Lim SK, et al. Visceral fat thickness measured by ultrasonography can estimate not only visceral obesity but also risks of cardiovascular and metabolic diseases. Am J Clin Nutr. 2004; 79(4): 593-9.
23. Ribeiro-Filho FF, Faria AN, Azjen S, Zanella MT, Ferreira SR. Methods of estimation of visceral fat: advantages of ultrasonography. Obes Res. 2003; 11(12): 1488-94.
24. Haymes EM, Lundegren HM, Loomis JL, Buskirk ER. Validity of the ultrasonic technique as a method of measuring subcutaneous adipose tissue. Ann Hum Biol. 1976; 3(3): 245-51.
25. Ebrahim S, Papacosta O, Whincup P, Wannamethee G, Walker M, Nicolaides AN, et al. Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women: the British Regional Heart Study. Stroke. 1999; 30(4): 841-50.
26. Belhassen L, Carville C, Pelle G, Monin JL, Teiger E, Duval-Moulin AM, et al. Evaluation of carotid artery and aortic intima-media thickness measurements for exclusion of significant coronary atheroscle rosis in patients scheduled for heart valve surgery. J Am Coll Cardiol. 2002; 39(7): 1139-44.
27. Sohrabpour AA, Rezvan H, Amini-Kafiabad S, Dayhim MR, Merat S, Pourshams A. Prevalence of nonalcoholic steatohepatitis in Iran: A population based study. Mid East J Digest Dis. 2010; 2: 14-9.
28. Jamali R, Khonsari M, Merat S, Khoshnia M, Jafari E, Bahram Kal- hori A, et al. Persistent alanine aminotransferase elevation among the general Iranian population: prevalence and causes. World J Gastroenterol. 2008; 14(18): 2867-71.
29. Emsley R, Dunn G, White IR. Mediation and moderation of treatment effects in randomised controlled trials of complex interventions. Stat Methods Med Res. 2010; 19(3): 237-70.
30. Schulz KF, Grimes DA. Multiplicity in randomised trials II: subgroup and interim analyses. Lancet. 2005; 365(9471): 1657-61.
31. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002; 123(3): 745-50.
32. Verma S, Jensen D, Hart J, Mohanty SR. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int. 2013; 33(9): 1398-405.
33. Sorrentino P, Tarantino G, Conca P, Perrella A, Terracciano ML, Vecchione R, et al. Silent non-alcoholic fatty liver disease-a clinical-histological study. J Hepatol. 2004; 41(5): 751-7.
34. Radmard AR, Merat S, Kooraki S, Ashrafi M, Keshtkar A, Sharafkhah M, et al. Gallstone disease and obesity: A population-based study on abdominal fat distribution and gender differences. Ann Hepatol. 2015. [In press]